These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 11915174

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK.
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [Abstract] [Full Text] [Related]

  • 3. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
    Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg LS, Spitler LE, Church C, O'Connor AA, Beutel LD.
    Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
    Dillman R, Barth N, Vandermolen L, Mahdavi K, Beutel L, de Leon C, DePriest C, Nayak S.
    Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
    [Abstract] [Full Text] [Related]

  • 7. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.
    Dillman RO, DeLeon C, Beutel LD, Barth NM, Schwartzberg LS, Spitler LE, Garfield DH, O'Connor AA, Nayak SK.
    Crit Rev Oncol Hematol; 2001 Oct; 39(1-2):115-23. PubMed ID: 11418308
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma.
    Dillman RO, DePriest C, DeLeon C, Barth NM, Schwartzberg LS, Beutel LD, Schiltz PM, Nayak SK.
    Cancer Biother Radiopharm; 2007 Jun; 22(3):309-21. PubMed ID: 17651037
    [Abstract] [Full Text] [Related]

  • 10. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.
    Dillman R, Selvan S, Schiltz P, Peterson C, Allen K, Depriest C, McClay E, Barth N, Sheehy P, de Leon C, Beutel L.
    Cancer Biother Radiopharm; 2004 Oct; 19(5):658-65. PubMed ID: 15650459
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, Escobar A, Ginesta A, Reyes D, González R, Mendoza-Naranjo A, Larrondo M, Compán A, Ferrada C, Salazar-Onfray F.
    J Clin Oncol; 2009 Feb 20; 27(6):945-52. PubMed ID: 19139436
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
    Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K.
    Cancer Biother Radiopharm; 2009 Jun 20; 24(3):311-9. PubMed ID: 19538053
    [Abstract] [Full Text] [Related]

  • 14. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.
    Gynecol Oncol; 2006 Mar 20; 100(3):469-78. PubMed ID: 16249018
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
    Schreiber S, Kämpgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Küpcü Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe RE, Voigt T, Weber HA, Pehamberger H, Mertelsmann R, Bröcker EB, Wolff K, Stingl G.
    Hum Gene Ther; 1999 Apr 10; 10(6):983-93. PubMed ID: 10223732
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM.
    Clin Cancer Res; 1998 Mar 10; 4(3):619-27. PubMed ID: 9533529
    [Abstract] [Full Text] [Related]

  • 18. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
    Dillman RO, Cornforth AN, Nistor GI, McClay EF, Amatruda TT, Depriest C.
    J Immunother Cancer; 2018 Mar 06; 6(1):19. PubMed ID: 29510745
    [Abstract] [Full Text] [Related]

  • 19. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA, Rimoldi D, Liénard D, Carrel S, Lejeune F, Dietrich PY, Cerottini JC, Romero P.
    Clin Cancer Res; 1997 May 06; 3(5):685-96. PubMed ID: 9815737
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.